title: A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
abstract: Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a consensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.
authors.affiliation: Ozarks CCOP, Springfield, MO.
authors.forename: J W
authors.initials: JW
authors.lastname: Goodwin
authors.forename: J
authors.initials: J
authors.lastname: Crowley
authors.forename: H J
authors.initials: HJ
authors.lastname: Eyre
authors.forename: B
authors.initials: B
authors.lastname: Stafford
authors.forename: K A
authors.initials: KA
authors.lastname: Jaeckle
authors.forename: J J
authors.initials: JJ
authors.lastname: Townsend
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D008579:Meningioma / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D016879:Salvage Therapy; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D013629:Tamoxifen